ObjectiveTo compare the degree of benign bone marrow uptake of
18F-fluorodeoxyglucose (18F-FDG) between Hodgkin
lymphoma patients with and without B symptoms.Materials and MethodsWe analyzed the medical charts of 74 Hodgkin lymphoma patients who underwent
18F-FDG positron emission tomography/computed tomography
(PET/CT) prior to the initiation of therapy between October 2010 and
September 2013. In all of the patients, the bone marrow biopsy was negative
and the 18F-FDG PET/CT images did not suggest bone marrow
involvement. Of the 74 patients evaluated, 54 presented inflammatory (B)
symptoms and 20 did not. Regions of interest (ROIs) were drawn on the
sternum, the proximal thirds of the humeri, the proximal thirds of the
femora, and both iliac wings (totaling seven ROIs per patient). To compare
the patients with and without B symptoms, in terms of standardized uptake
values (SUVs) for the seven ROIs, we used the Mann-Whitney U test.ResultsFor six of the ROIs, the SUVs were higher in the patients with B symptoms
than in those without, and the difference was statistically significant
(p < 0.05). There was also a tendency toward a
statistically significant difference between the two groups in terms of the
SUV for the right iliac wing ROI (p = 0.06).ConclusionIn our sample, the presence of B symptoms was associated with increased
18F-FDG uptake in bone marrow.